School of Medical Sciences, Faculty of Medicine, UNSW Australia, Sydney, NSW 2052, Australia.
The Kirby Institute, UNSW Australia, Sydney, NSW 2052, Australia.
Sci Rep. 2017 Jan 31;7:41719. doi: 10.1038/srep41719.
Resistance against new hepatitis C virus (HCV) antivirals is an area of increasing interest. Resistance-associated substitutions (RASs) have been identified in treatment-naïve individuals, but pressures driving treatment-independent RAS emergence are poorly understood. We analysed the longitudinal evolution of RASs in twelve participants with early acute HCV infections. Full-genome deep sequences were analysed for changes in RAS frequency within NS3, NS5A and NS5B-coding regions over the course of the infection. Emergence of RASs relevant only to the polymerase non-nucleoside inhibitors (NNI) was detected, and these lay within CD8+ T-cell epitopes. Conversely, the loss of NNI RASs over time appeared likely to be driven by viral fitness constraints. These results highlight the importance of monitoring CD8+ T cell epitope-associated RASs in populations with dominant HLA types.
对新的丙型肝炎病毒 (HCV) 抗病毒药物的耐药性是一个日益受到关注的领域。在未经治疗的个体中已经发现了耐药相关替代 (RAS),但驱动治疗独立性 RAS 出现的压力却知之甚少。我们分析了 12 名急性 HCV 感染早期患者的 RAS 纵向演变。对 NS3、NS5A 和 NS5B 编码区的全长深度序列进行了分析,以了解感染过程中 RAS 频率的变化。检测到仅与聚合酶非核苷抑制剂 (NNI) 相关的 RAS 的出现,这些 RAS 位于 CD8+ T 细胞表位内。相反,随着时间的推移,NNI RAS 的丢失似乎很可能是由病毒适应性限制驱动的。这些结果强调了在具有主要 HLA 类型的人群中监测 CD8+ T 细胞表位相关 RAS 的重要性。